Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis

39 Páginas.

Autores:

Tipo de recurso:

Fecha de publicación:: 2016

Institución:: Universidad de la Sabana

Repositorio:: Repositorio Universidad de la Sabana

Idioma:: spa

id	REPOUSABAN_ebb0a21ce9f51e4e27c2f23f3d18d00f
oai_identifier_str	oai:intellectum.unisabana.edu.co:10818/28731
network_acronym_str	REPOUSABAN
network_name_str	Repositorio Universidad de la Sabana
repository_id_str
dc.title.none.fl_str_mv	Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis
title	Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis
spellingShingle	Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis Botánica médica Farmacología experimental Marihuana -- Uso terapéutico Plantas alucinógenas
title_short	Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis
title_full	Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis
title_fullStr	Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis
title_full_unstemmed	Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis
title_sort	Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis
dc.contributor.none.fl_str_mv	Díaz Quijano, Diana Marcela
dc.subject.none.fl_str_mv	Botánica médica Farmacología experimental Marihuana -- Uso terapéutico Plantas alucinógenas
topic	Botánica médica Farmacología experimental Marihuana -- Uso terapéutico Plantas alucinógenas
description	39 Páginas.
publishDate	2016
dc.date.none.fl_str_mv	2016-11-24T21:09:45Z 2016-11-24T21:09:45Z 2016-11-24 2016
dc.type.none.fl_str_mv	Tesis/Trabajo de grado - Especialización http://purl.org/coar/resource_type/c_7a1f Texto info:eu-repo/semantics/other http://purl.org/redcol/resource_type/COther info:eu-repo/semantics/acceptedVersion
status_str	acceptedVersion
dc.identifier.none.fl_str_mv	Cook J., Lloyd-Jones D., Ogden E. Medical use of cannabis: an addiction medicine perspective. Internal Medicine Journal. 2015; 45: 677-681. Whiting P.F., Wolff R.F., Deshpande S, et al. Cannabinoids for medical Use: A Systematic Review and Meta-analysis. The Journal of the American Medical Association. 2015; 313(24): 2456-2473 Alpár A, Di Marzo V, Harkany T. At the tip of an iceberg: Prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring. Biological Psychiatry 2016; 79(7):e33-e45. FDA.gov [Internet] Estados Unidos. FDA and Marijuana: Questions and Answers [Fecha de consulta 23 de octubre de 2016]. Disponible en: http://www.fda.gov/newsevents/publichealthfocus/ucm421168.htm Ministerio de Salud y Protección Social. República de Colombia. Decreto 2467 de 2015. [Fecha de consulta 23 de octubre de 2016]. Disponible en: http://wp.presidencia.gov.co/sitios/normativa/decretos/2015/Decretos2015/DECRE TO%202467%20DEL%2022%20DE%20DICIEMBRE%20DE%202015.pdf Pertwee R. Cannabinoid pharmacology: the first 66 years. British Journal of Pharmacology. 2006; 147: S163¿S171. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264¿269 Shea BJ, Grimshaw JM, Wells GA, et al.: Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007, 7: 10. . Scottish Intercollegiate Guidelines Network [Internet]. Search Filters. Scotland: SIGN 2001-2014. [actualizado 27 Ago 2015; citado 23 Dic 2015]. Disponible en: http://hiru.mcmaster.ca/hiru/HIRU_Hedges_home.aspx Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159¿174 Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al The NewcastleOttawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. [Fecha de consulta 23 de diciembre de 2016]. Disponible en: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012; 65: 934¿939 Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS ONE 11(3): e0150970. doi:10.1371/journal. pone.0150970 Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of FDG-PET studies to diagnose lung cancer. JAMA. 2015; 313: 419. Babson K., Boden M., Bonn-Miller M. Sleep Quality Moderates the Relation between Depression Symptoms and Problematic Cannabis Use among Medical Cannabis Users. The American Journal of Drug and Alcohol Abuse. 2013; 39 (3): 211-216. . Belendiuk K., Babson K., Vandrey R., Bonn-Miller M. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. Addictve Behaviors. 2015; 50: 178-181 . Harris D., Jones R., Rank R., Nath R., Hernandez E., Goldstein K., Meldenson J. Self-Reported Marijuana Effects and Characteristics of 100 San Francisco Medical Marijuana Club Members. Journal of Addictive Diseases. 2000; 19 (3): 89- 103. Harris G., Dupuis L., Mugford G., Johnston L., Haase D., Page G., Haldane H., Harris N., Midodzi W., Dow G. Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada. Can J Infect Dis Med Microbiol. 2014; 25 (1): e1-e7. Ilgen M., Bohnert K., Kleinberg F., Jannausch M., Bohner A., Walton M., Blow F. Characteristics of adults seeking medical marijuana certification. Drug and Alcohol Dependence. 2013; 132: 654-659. Swartz R. Medical marijuana users in substance abuse treatment. Harm Reduction Journal. 2010; 7: 1-9. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic noncancer pain: Results of a prospective survey. Pain. 2003; 102: 211-216. Bonn-Miller M., Trafton J. Prevalence of Cannabis Use Disorder Diagnoses Among Veterans in 2002, 2008, and 2009. Psychological Services. 2012; 9 (4): 404-416. Cerdá M., Wall M., Keyes K., Galea S., Hasin D. Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug and Alcohol Dependence. 2012; 120: 22-27. D¿Amico E., Miles J., Tucker J. Gateway to Curiosity: Medical Marijuana Ads and Intention and Use During Middle School. Psychology of Addictive Behaviors. 2015; 29 (3): 613-619. . Degenhardt L., Lintzeris N., Campbell G., Bruno R., Cohen., Farrell M., Hall W. Experience of adjunctive cannabis use for chronic non-cancer pain:Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence. 2015; 147: 144-150. . Ghandour L., El Sayed D., Martins S., Martins S. Prevalence and patterns of commonly abused psychoactive prescription drugs in a sample of university students from Lebanon: An opportunity for cross-cultural comparisons. Drug and Alcohol Dependence. 2012; 121: 110-117. Gunderson E., Haughey H., Ait-Daoud N., Joshi A., Hart C. A Survey of Synthetic Cannabinoid Consumption by Current Cannabis Users. Substance Abuse. 2014; 35: 184-189. Kim H., Anderson J., Saghafi O., Heard K., Monte A. Cyclic Vomiting Presentations Following Marijuana Liberalization in Colorado. Academic Emergency Medicine. 2015; 22 (6): 694-699. Pacula RL, Powell D, Heaton P, Sevigny EL. Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. Journal of Policy Analysis & Management. 2015; 34 (1): 7-31. Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min S-J, Sakai JT. Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003¿11. Drug and Alcohol Dependence. 2014; 140: 145-155. https://hdl.handle.net/10818/28731 263029 TE08800
identifier_str_mv	Cook J., Lloyd-Jones D., Ogden E. Medical use of cannabis: an addiction medicine perspective. Internal Medicine Journal. 2015; 45: 677-681. Whiting P.F., Wolff R.F., Deshpande S, et al. Cannabinoids for medical Use: A Systematic Review and Meta-analysis. The Journal of the American Medical Association. 2015; 313(24): 2456-2473 Alpár A, Di Marzo V, Harkany T. At the tip of an iceberg: Prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring. Biological Psychiatry 2016; 79(7):e33-e45. FDA.gov [Internet] Estados Unidos. FDA and Marijuana: Questions and Answers [Fecha de consulta 23 de octubre de 2016]. Disponible en: http://www.fda.gov/newsevents/publichealthfocus/ucm421168.htm Ministerio de Salud y Protección Social. República de Colombia. Decreto 2467 de 2015. [Fecha de consulta 23 de octubre de 2016]. Disponible en: http://wp.presidencia.gov.co/sitios/normativa/decretos/2015/Decretos2015/DECRE TO%202467%20DEL%2022%20DE%20DICIEMBRE%20DE%202015.pdf Pertwee R. Cannabinoid pharmacology: the first 66 years. British Journal of Pharmacology. 2006; 147: S163¿S171. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264¿269 Shea BJ, Grimshaw JM, Wells GA, et al.: Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007, 7: 10. . Scottish Intercollegiate Guidelines Network [Internet]. Search Filters. Scotland: SIGN 2001-2014. [actualizado 27 Ago 2015; citado 23 Dic 2015]. Disponible en: http://hiru.mcmaster.ca/hiru/HIRU_Hedges_home.aspx Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159¿174 Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al The NewcastleOttawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. [Fecha de consulta 23 de diciembre de 2016]. Disponible en: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012; 65: 934¿939 Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS ONE 11(3): e0150970. doi:10.1371/journal. pone.0150970 Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of FDG-PET studies to diagnose lung cancer. JAMA. 2015; 313: 419. Babson K., Boden M., Bonn-Miller M. Sleep Quality Moderates the Relation between Depression Symptoms and Problematic Cannabis Use among Medical Cannabis Users. The American Journal of Drug and Alcohol Abuse. 2013; 39 (3): 211-216. . Belendiuk K., Babson K., Vandrey R., Bonn-Miller M. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. Addictve Behaviors. 2015; 50: 178-181 . Harris D., Jones R., Rank R., Nath R., Hernandez E., Goldstein K., Meldenson J. Self-Reported Marijuana Effects and Characteristics of 100 San Francisco Medical Marijuana Club Members. Journal of Addictive Diseases. 2000; 19 (3): 89- 103. Harris G., Dupuis L., Mugford G., Johnston L., Haase D., Page G., Haldane H., Harris N., Midodzi W., Dow G. Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada. Can J Infect Dis Med Microbiol. 2014; 25 (1): e1-e7. Ilgen M., Bohnert K., Kleinberg F., Jannausch M., Bohner A., Walton M., Blow F. Characteristics of adults seeking medical marijuana certification. Drug and Alcohol Dependence. 2013; 132: 654-659. Swartz R. Medical marijuana users in substance abuse treatment. Harm Reduction Journal. 2010; 7: 1-9. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic noncancer pain: Results of a prospective survey. Pain. 2003; 102: 211-216. Bonn-Miller M., Trafton J. Prevalence of Cannabis Use Disorder Diagnoses Among Veterans in 2002, 2008, and 2009. Psychological Services. 2012; 9 (4): 404-416. Cerdá M., Wall M., Keyes K., Galea S., Hasin D. Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug and Alcohol Dependence. 2012; 120: 22-27. D¿Amico E., Miles J., Tucker J. Gateway to Curiosity: Medical Marijuana Ads and Intention and Use During Middle School. Psychology of Addictive Behaviors. 2015; 29 (3): 613-619. . Degenhardt L., Lintzeris N., Campbell G., Bruno R., Cohen., Farrell M., Hall W. Experience of adjunctive cannabis use for chronic non-cancer pain:Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence. 2015; 147: 144-150. . Ghandour L., El Sayed D., Martins S., Martins S. Prevalence and patterns of commonly abused psychoactive prescription drugs in a sample of university students from Lebanon: An opportunity for cross-cultural comparisons. Drug and Alcohol Dependence. 2012; 121: 110-117. Gunderson E., Haughey H., Ait-Daoud N., Joshi A., Hart C. A Survey of Synthetic Cannabinoid Consumption by Current Cannabis Users. Substance Abuse. 2014; 35: 184-189. Kim H., Anderson J., Saghafi O., Heard K., Monte A. Cyclic Vomiting Presentations Following Marijuana Liberalization in Colorado. Academic Emergency Medicine. 2015; 22 (6): 694-699. Pacula RL, Powell D, Heaton P, Sevigny EL. Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. Journal of Policy Analysis & Management. 2015; 34 (1): 7-31. Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min S-J, Sakai JT. Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003¿11. Drug and Alcohol Dependence. 2014; 140: 145-155. 263029 TE08800
url	https://hdl.handle.net/10818/28731
dc.language.none.fl_str_mv	spa
language	spa
dc.rights.none.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ restrictedAccess
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_16ec
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ restrictedAccess http://purl.org/coar/access_right/c_16ec
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Universidad de La Sabana Universidad de La Sabana. Especialización en Farmacología Clínica Facultad de Medicina
publisher.none.fl_str_mv	Universidad de La Sabana Universidad de La Sabana. Especialización en Farmacología Clínica Facultad de Medicina
dc.source.none.fl_str_mv	Universidad de La Sabana Intellectum Repositorio Universidad de la Sabana
institution	Universidad de la Sabana
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1860891911080902656
spelling	Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisisBotánica médicaFarmacología experimentalMarihuana -- Uso terapéuticoPlantas alucinógenas39 Páginas.Introducción: El uso de cannabis para fines medicinales ha crecido progresivamente en diversas regiones del mundo, llevando a la búsqueda de aprobación por parte de las autoridades regulatorias. En este contexto, resulta importante evaluar la seguridad de esta alternativa en términos de su desvío hacia uso recreacional. Métodos: Se realizó un búsqueda sistematica en las bases de datos de MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily Update, Embase, PsycINFO, Lilacs y Cinahl Plus desde el origen hasta enero de 2016. Se incluyeron estudios de diseño observacional que reportaran información de desvío hacia uso recreativo de cannabinoides utilizados con fines terapéuticos y se siguieron las procedimientos metodológicos estándar esperados por el grupo Cochrane. Resultados: Trece estudios cumplieron con los criterios de inclusión. Doce de ellos tuvieron un diseño transversal y uno prospectivo. El porcentaje de pacientes con condiciones físicas o mentales con reporte de desvío de cannabis medicinal varía entre un 0% a un 94.4%. Así mismo, se tuvo un porcentaje de 24% y 73.7% de personas que desvían el uso de cannabis medicinal de pacientes con indicación. No hubo desvío cuando se utilizaron cannabinoides con presentación farmacológica definida. La mayoría de estudios analizados tuvieron un riesgo de sesgo moderado. Conclusiones: La evidencia encontrada es heterogenea y no puede establecerse causalidad ante el diseño de los estudios evaluados. Es posible que el riesgo de desvio sea mínimo con presentaciones farmacológicas definidas. ¿¿¿Universidad de La SabanaUniversidad de La Sabana.Especialización en Farmacología ClínicaFacultad de MedicinaDíaz Quijano, Diana MarcelaFeliciano Alfonso, John EdwinVargas Bautista, Marie Fernanda2016-11-24T21:09:45Z2016-11-24T21:09:45Z2016-11-242016Tesis/Trabajo de grado - Especializaciónhttp://purl.org/coar/resource_type/c_7a1fTextoinfo:eu-repo/semantics/otherhttp://purl.org/redcol/resource_type/COtherinfo:eu-repo/semantics/acceptedVersionapplication/pdfCook J., Lloyd-Jones D., Ogden E. Medical use of cannabis: an addiction medicine perspective. Internal Medicine Journal. 2015; 45: 677-681.Whiting P.F., Wolff R.F., Deshpande S, et al. Cannabinoids for medical Use: A Systematic Review and Meta-analysis. The Journal of the American Medical Association. 2015; 313(24): 2456-2473Alpár A, Di Marzo V, Harkany T. At the tip of an iceberg: Prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring. Biological Psychiatry 2016; 79(7):e33-e45.FDA.gov [Internet] Estados Unidos. FDA and Marijuana: Questions and Answers [Fecha de consulta 23 de octubre de 2016]. Disponible en: http://www.fda.gov/newsevents/publichealthfocus/ucm421168.htmMinisterio de Salud y Protección Social. República de Colombia. Decreto 2467 de 2015. [Fecha de consulta 23 de octubre de 2016]. Disponible en: http://wp.presidencia.gov.co/sitios/normativa/decretos/2015/Decretos2015/DECRE TO%202467%20DEL%2022%20DE%20DICIEMBRE%20DE%202015.pdfPertwee R. Cannabinoid pharmacology: the first 66 years. British Journal of Pharmacology. 2006; 147: S163¿S171.Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151(4):264¿269Shea BJ, Grimshaw JM, Wells GA, et al.: Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007, 7: 10.. Scottish Intercollegiate Guidelines Network [Internet]. Search Filters. Scotland: SIGN 2001-2014. [actualizado 27 Ago 2015; citado 23 Dic 2015]. Disponible en: http://hiru.mcmaster.ca/hiru/HIRU_Hedges_home.aspxLandis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159¿174Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al The NewcastleOttawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. [Fecha de consulta 23 de diciembre de 2016]. Disponible en: http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspHoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012; 65: 934¿939Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS ONE 11(3): e0150970. doi:10.1371/journal. pone.0150970Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of FDG-PET studies to diagnose lung cancer. JAMA. 2015; 313: 419.Babson K., Boden M., Bonn-Miller M. Sleep Quality Moderates the Relation between Depression Symptoms and Problematic Cannabis Use among Medical Cannabis Users. The American Journal of Drug and Alcohol Abuse. 2013; 39 (3): 211-216.. Belendiuk K., Babson K., Vandrey R., Bonn-Miller M. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. Addictve Behaviors. 2015; 50: 178-181. Harris D., Jones R., Rank R., Nath R., Hernandez E., Goldstein K., Meldenson J. Self-Reported Marijuana Effects and Characteristics of 100 San Francisco Medical Marijuana Club Members. Journal of Addictive Diseases. 2000; 19 (3): 89- 103.Harris G., Dupuis L., Mugford G., Johnston L., Haase D., Page G., Haldane H., Harris N., Midodzi W., Dow G. Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada. Can J Infect Dis Med Microbiol. 2014; 25 (1): e1-e7.Ilgen M., Bohnert K., Kleinberg F., Jannausch M., Bohner A., Walton M., Blow F. Characteristics of adults seeking medical marijuana certification. Drug and Alcohol Dependence. 2013; 132: 654-659.Swartz R. Medical marijuana users in substance abuse treatment. Harm Reduction Journal. 2010; 7: 1-9.Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic noncancer pain: Results of a prospective survey. Pain. 2003; 102: 211-216.Bonn-Miller M., Trafton J. Prevalence of Cannabis Use Disorder Diagnoses Among Veterans in 2002, 2008, and 2009. Psychological Services. 2012; 9 (4): 404-416.Cerdá M., Wall M., Keyes K., Galea S., Hasin D. Medical marijuana laws in 50 states: Investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug and Alcohol Dependence. 2012; 120: 22-27.D¿Amico E., Miles J., Tucker J. Gateway to Curiosity: Medical Marijuana Ads and Intention and Use During Middle School. Psychology of Addictive Behaviors. 2015; 29 (3): 613-619.. Degenhardt L., Lintzeris N., Campbell G., Bruno R., Cohen., Farrell M., Hall W. Experience of adjunctive cannabis use for chronic non-cancer pain:Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence. 2015; 147: 144-150.. Ghandour L., El Sayed D., Martins S., Martins S. Prevalence and patterns of commonly abused psychoactive prescription drugs in a sample of university students from Lebanon: An opportunity for cross-cultural comparisons. Drug and Alcohol Dependence. 2012; 121: 110-117.Gunderson E., Haughey H., Ait-Daoud N., Joshi A., Hart C. A Survey of Synthetic Cannabinoid Consumption by Current Cannabis Users. Substance Abuse. 2014; 35: 184-189.Kim H., Anderson J., Saghafi O., Heard K., Monte A. Cyclic Vomiting Presentations Following Marijuana Liberalization in Colorado. Academic Emergency Medicine. 2015; 22 (6): 694-699.Pacula RL, Powell D, Heaton P, Sevigny EL. Assessing the effects of medical marijuana laws on marijuana use: the devil is in the details. Journal of Policy Analysis & Management. 2015; 34 (1): 7-31.Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min S-J, Sakai JT. Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003¿11. Drug and Alcohol Dependence. 2014; 140: 145-155.https://hdl.handle.net/10818/28731263029TE08800Universidad de La SabanaIntellectum Repositorio Universidad de la SabanaspaAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/restrictedAccesshttp://purl.org/coar/access_right/c_16ecoai:intellectum.unisabana.edu.co:10818/287312025-12-11T18:04:08Z

Cannabinoides medicinales y su desvío para uso recreativo: Revisión sistemática de la literatura y meta análisis

Publicaciones similares